Physician profile
Heena Shah Patel
NPI 1881916864
$427,982.74
in general payments reported to CMS, 2019-2025
41 companies · $70K in 2025
The $70K reported for 2025 was more than what 97% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $16K · 2021: $33K · 2022: $30K · 2023: $140K · 2024: $99K · 2025: $70K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $202K · Travel and Lodging: $68K · Consulting Fee: $22K · Food and Beverage: $17K · Education: $532 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $202,165.00 |
| Travel and Lodging | $67,500.66 |
| Consulting Fee | $21,766.50 |
| Food and Beverage | $17,157.66 |
| Education | $531.71 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $391,960.28 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Incyte Corporation | $8,304.98 | 2022-2025 | Opzelura |
| Genzyme Corporation | $7,519.33 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $5,493.00 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $3,441.31 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Regeneron Healthcare Solutions, INC. | $1,900.03 | 2019-2025 | Dupixent |
| Csl Behring | $1,195.20 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Pfizer INC. | $1,184.48 | 2019-2025 | |
| Leo Pharma INC. | $940.17 | 2022-2025 | Adbry, Anzupgo |
| Abbvie INC. | $916.67 | 2021-2025 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $783.25 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Pharming Healthcare, INC. | $444.29 | 2020-2025 | Ruconest |
| Sanofi-Aventis U.S. LLC | $426.34 | 2019-2025 | |
| Optinose US, INC. | $381.18 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $364.45 | 2021-2025 | Orladeyo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $312.42 | 2019-2025 | Xolair |
| Amgen INC. | $279.19 | 2021-2025 | Tezspire, Actimmune |
| Novartis Pharmaceuticals Corporation | $249.33 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.64 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $195.97 | 2020-2021 | |
| Octapharma USA, INC. | $181.90 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $148.18 | 2025 | Neffy |
| Sunovion Pharmaceuticals INC. | $142.28 | 2019 | |
| Merck Sharp & Dohme LLC | $141.99 | 2021-2023 | |
| Genentech, INC. | $129.27 | 2020-2021 | |
| Blueprint Medicines Corporation | $115.26 | 2022-2024 | Ayvakit |
| Kaleo, INC. | $107.14 | 2020-2024 | Auvi-Q |
| Alk-Abello, INC | $87.02 | 2020-2025 | Grastek, Ragwitek, Odactra |
| Galderma Laboratories, L.P. | $75.97 | 2025 | Nemluvio |
| Grifols USA, LLC | $60.76 | 2024 | Prolastin-C Liquid |
| Shire North American Group INC | $54.91 | 2019 | |
| Horizon Therapeutics Plc | $42.50 | 2020-2021 | |
| Phadia US INC. | $39.47 | 2022-2023 | Immunocap |
| Hikma Pharmaceuticals USA | $33.27 | 2023 | Ryaltris |
| Mylan Specialty L.P. | $25.68 | 2019 | |
| Lilly USA, LLC | $24.74 | 2025 | Ebglyss, Taltz |
| Ionis Pharmaceuticals, INC. | $20.02 | 2025 | Dawnzera |
| Biocryst Pharmaceuticals, INC. | $19.15 | 2020 | |
| Bio Products Laboratory USA, INC. | $14.99 | 2022 | |
| Insmed, INC. | $13.73 | 2025 | Arikayce |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heena Shah Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.